PA-TRINSEO
Trinseo (“Trinseo” or “the Company”) (NYSE: TSE), a specialty material solutions provider, is helping advance the potential of sustainable plastics with the inauguration of its next generation, polymethyl methacrylate (PMMA) depolymerization plant in Rho, Italy. Scheduled to be commissioned in Q1 2024, this demonstration facility marks a pivotal step towards reshaping the plastics ecosystem as part of the circular economy. PMMA, renowned for its versatility in various applications, will be transformed through this advanced recycling and purification process where it can go back into the plastics value chain and support the goal of circularity. This depolymerization operation will be designed to enable the efficient recycling of end-of-life PMMA, as well as other difficult to recycle structures, which will ultimately be used to produce acrylic resins, sheets, and compounds containing recycled materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206633138/en/
Trinseo Manufacturing Operations, Rho, Italy. Site of future demonstration PMMA depolymerization facility. (Photo: Business Wire)
Depolymerization is a chemical recycling technology which is complementary to more traditional mechanical recycling processes. While mechanical recycling is vital to a successful circular economy, depolymerization creates brand new opportunities by reducing the polymer back to its constituent monomers. This allows for the recycling of a wider variety of PMMA-based materials, supporting an increase in recycled content and overall recycling rates, and helping reduce the manufacturing demand for virgin materials.
“Innovation in recycling technologies is imperative to effectively recycle various types of materials. This new facility is yet another major achievement towards a scalable system with the goal of making PMMA a truly circular material of high quality,” said Trinseo’s Chief Sustainability Officer, Francesca Reverberi. “When combined with our own in-house sourcing and treatment of collected materials through our Heathland recycling operation, our PMMA depolymerization plant will offer a high-performance solution for a world increasingly looking for new ways to address sustainability in the plastics supply chain,” added Reverberi.
Trinseo’s depolymerization facility is being developed around a continuous recovery model to produce high quality recycled PMMA that matches the quality of its virgin counterpart, promoting a circular plastics value chain without compromising performance. Using this advanced recycling technology, the introduction of recycled monomer into the supply chain helps support achieving targets for lowering carbon emissions, water consumption, and the conservation of natural resources, as indicated by the MMAtwo project's environmental benefits calculator. A shift towards PMMA depolymerization can help deliver sustainability benefits for consumers, manufacturers, and industries alike. From car lamps to signage and more, this technology creates the opportunity to give a range of everyday products a second life and beyond.
Material produced using the depolymerization process will be integrated as part of Trinseo's distinctive “R-Life” portfolio designed around a commitment to sustainability, covering both mechanically and chemically recycled PMMA grades. These products find applications across mobility, construction, and consumer goods, aligning with the growing demand for products that are developed with sustainability in mind.
About Trinseo
Trinseo (NYSE: TSE), a specialty material solutions provider, partners with companies to bring ideas to life in an imaginative, smart and sustainably focused manner by combining its premier expertise, forward-looking innovations and best-in-class materials to unlock value for companies and consumers.
From design to manufacturing, Trinseo taps into decades of experience in diverse material solutions to address customers’ unique challenges in a wide range of industries, including building and construction, consumer goods, medical and mobility.
Trinseo’s approximately 3,300 employees bring endless creativity to reimagining the possibilities with clients all over the world from the company’s locations in North America, Europe and Asia Pacific. Trinseo reported net sales of approximately $5.0 billion in 2022. Discover more by visiting www.trinseo.com and connecting with Trinseo on LinkedIn, Twitter, Facebook and WeChat.
Cautionary Note on Forward-Looking Statements
This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, forecasts, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like "expect," "anticipate," “believe,” "intend," "forecast," "outlook," "will," "may," "might," "see," "tend," "assume," "potential," "likely," "target," "plan," "contemplate," "seek," "attempt," "should," "could," "would" or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on our current expectations and assumptions regarding our business, the economy, our current indebtedness, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause future results to differ from those expressed by the forward-looking statements include, but are not limited to, our ability to successfully implement proposed restructuring initiatives, including the closure of certain plants and product lines, and to successfully generate cost savings and increase profitability; our ability to successfully execute our business and transformation strategy; increased costs or disruption in the supply of raw materials; increased energy costs; compliance with laws and regulations impacting our business; conditions in the global economy and capital markets; our ability to meet the covenants under our existing indebtedness; our ability to successfully investigate and remediate chemical releases on or from our sites, make related capital expenditures, reimburse third-party cleanup costs or settle potential regulatory penalties or other claims; and those discussed in our Annual Report on Form 10-K, under Part I, Item 1A —"Risk Factors" and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results, performance or achievements may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206633138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia
SmartStream Brings AI-Powered Data Management to the Insurance Sector12.6.2025 09:00:00 CEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) and solutions provider, has announced the expansion of its AI-driven reconciliation and data management platform, SmartStream Air, into the insurance sector. This move aims to help insurers tackle fragmented data challenges, reduce operational costs, and strengthen compliance through robust audit trails. As the insurance industry struggles with limited digital maturity, it faces mounting pressure from increasing transaction volumes, persistent data quality issues, and the complex demands of evolving regulations such as IFRS 17 and DORA. In this environment, the need for advanced, rapidly deployable SaaS data management solutions has never been more urgent. Addressing these challenges requires a fundamental transformation in how insurers manage systems, streamline operations, and ensure data integrity across the enterprise. SmartStream Air leverages cutting-edge AI to reconcile and manage high volumes of data, for exampl
Westlake Epoxy Announces Strategic Collaboration With Alpha Recyclage Composites to Advance Composites Recycling12.6.2025 08:00:00 CEST | Press release
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy will collaborate with Alpha Recyclage Composites to support them in scaling up the recycling capacity for carbon fiber composite materials. This collaboration will provide support to Westlake’s composite customers in their development of improved circular options for both production (scrap or off spec composite materials that otherwise become waste) and end-of-life waste. The recovery of the carbon fibers from composite materials for reuse in new or emerging applications aims to establish a more sustainable alternative to traditional disposal methods such as landfilling and incineration. Alpha Recyclage Composites, a family-owned company based in Toulouse and Castelsarrasin, France, specializes in recycling carbon-fibers-reinforced composites through a patented steam pyrolysis process. This innovative technology preserves the performance qualities of the carbon fibers used in composite materials recovered from applica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom